Pseudophenmetrazine

Pseudophenmetrazine is a stimulant compound related to phenmetrazine that was developed in the 1960s and used for the treatment of obesity.

History

Pseudophenmetrazine was developed during the 1960s as part of an effort to find a replacement for the anorectic drug phenmetrazine, which had been widely abused. It was hoped that pseudophenmetrazine would have a similar effect on weight loss without the potential for abuse, but in practice it was found to be less effective and less well tolerated than the parent compound.

Pharmacology

Pseudophenmetrazine acts as a norepinephrine-dopamine releasing agent (NDRA), with 10x lower potency than the parent compound phenmetrazine. It is also less potent than amphetamine at releasing dopamine, but is significantly more potent at releasing norepinephrine.

Side Effects

The side effects of pseudophenmetrazine are similar to those of other stimulants and include insomnia, anxiety, increased heart rate and blood pressure, and potential for addiction.

Legal Status

Pseudophenmetrazine is currently a Schedule III controlled substance in the United States under the Controlled Substances Act.

See Also

• Phenmetrazine
• Amphetamine
• Controlled Substances Act

Pseudophenmetrazine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski